Semaglutide Weight Management and Cardiovascular Risk Reduction
ONWARDS 5 included real-world elements and compared once-
weekly insulin icodec with once-daily basal insulins in T2D
Onwards 5 enrolled 1085 patients with Type 2 Diabetes
Once-weekly insulin icodec + dosing guide app
± non-insulin anti-diabetic drugs
Once-daily basal insulin analogues
R
1:1
± non-insulin anti-diabetic drugs
52 Weeks
5 weeks
follow-up
Objective:
• To confirm the efficacy of HbA1c and safety of insulin icodec with a
dosing guide app providing dosing recommendation vs once-daily
basal insulin analogues, both in combination with any non-insulin
antidiabetic medication in insulin-naïve T2D patients
Trial design:
The trial included real-world elements to reflect real-world insulin use
with fewer planned site visits, no upper limit on HbA1c and minimal
exclusion criteria.
Key endpoints:
•
Change in HbA1c
•
Patient Related Outcomes (PROs)
T2D: Type 2 diabetes; R: Randomisation. Once-daily basal insulin analogues include insulin degludec and insulin glargine U100 and U300
•
Level 2 and 3 hypoglycaemia events
Inclusion criteria:
Insulin-naïve people with type 2 diabetes
No limitations on use of oral antidiabetic treatments
Age ≥18 years, HbA1c > 7.0%View entire presentation